Tokyo, Dec. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059272) titled 'Specified drug use-results survey of TALVEY Subcutaneous Injection in patients with relapsed or refractory multiple myeloma' on Dec. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - relapsed or refractory multiple myeloma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the safety of subcutaneous injection of TALVEY in patients with relapsed or refractory multiple myeloma (only when standard treatment is difficult) who receive this drug for the first time under routine clinical practice.
In ...